Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection
Phase 1
Not yet recruiting
- Conditions
- Long COVID
- Interventions
- Procedure: Adipose Tissue HarvestBiological: ATCell
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- American CryoStem Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT05669261
ATCellâ„¢ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion
Phase 1
Active, not recruiting
- Conditions
- Post-Concussion Syndrome
- Interventions
- Drug: 150 Adipose Derived Stem Cell InfusionDrug: 300 Adipose Derived Stem Cell InfusionDrug: Placebo InfusionDrug: 50 Adipose Derived Stem Cell Infusion
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- American CryoStem Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT04744051
- Locations
- 🇺🇸
BioSolutions Clinical Research Center, La Mesa, California, United States
Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis
Phase 1
Terminated
- Conditions
- Multiple Sclerosis
- Interventions
- Biological: Autologous adipose derived mesenchymal cells
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- American CryoStem Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT02326935
- Locations
- 🇰🇾
The Da Vinci Center, George Town, Cayman Islands
© Copyright 2025. All Rights Reserved by MedPath